{
    "data": [
        {
            "id": "4552179",
            "type": "article",
            "attributes": {
                "publishOn": "2022-11-02T16:36:45-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1364097824/image_1364097824.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte A Buy As Revenue From Opzelura Ramps",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "418099",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4552179-incyte-a-buy-as-revenue-from-opzelura-ramps"
            }
        },
        {
            "id": "4543907",
            "type": "article",
            "attributes": {
                "publishOn": "2022-09-29T16:26:05-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1348321043/image_1348321043.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "106553",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "411775",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4543907-incyte-corp-improving-growth-prospects-and-favorable-chart"
            }
        },
        {
            "id": "4524018",
            "type": "article",
            "attributes": {
                "publishOn": "2022-07-18T14:50:06-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1331863711/image_1331863711.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Corp. Should Move Higher (Technical Analysis)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "101430",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "383164",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4524018-incyte-corp-should-move-higher-technical-analysis"
            }
        },
        {
            "id": "4518891",
            "type": "article",
            "attributes": {
                "publishOn": "2022-06-17T03:01:27-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1310024666/image_1310024666.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: Growth Drivers Are Coming",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "378539",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4518891-incyte-growth-drivers-buy"
            }
        },
        {
            "id": "4501368",
            "type": "article",
            "attributes": {
                "publishOn": "2022-04-14T06:14:05-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1156927918/image_1156927918.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte Is A Buy As Ruxolitinib Ramps Revenue And Pipeline Matures",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24757",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "369703",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4501368-incyte-buy-ruxolitinib-revenue-pipeline-matures"
            }
        },
        {
            "id": "4496763",
            "type": "article",
            "attributes": {
                "publishOn": "2022-03-21T08:54:54-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1293772875/image_1293772875.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: All Attention On Opzelura",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104870",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "366320",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4496763-incyte-all-atention-on-opzelura"
            }
        },
        {
            "id": "4481096",
            "type": "article",
            "attributes": {
                "publishOn": "2022-01-24T00:39:38-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1333810802/image_1333810802.jpg",
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Incyte: Still Has Room To Grow",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "104805",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "358280",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1092",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/4481096-incyte-incy-still-has-room-to-grow"
            }
        }
    ]
}